Eubiocard

It is used in ischemic heart disease and clinical situations in which inhibition of platelet aggregation is targeted.

Type and content of packaging

PVC/PVDC/Aluminum blister contains 10 or 15 enteral tablets. In package: 15, 30, 60, 90, 120 enteral tablets. Commercial packaging is a cardboard box containing a patient leaflet and a blister with the corresponding number of tablets.

Pharmaceutical form

Enteral tablet. Round tablets, white to cream color, convex on both sides, 8 mm in diameter.

Dosage and administration

Oral administration. The enteral tablet has a special coating that prevents disintegration in the stomach, protecting against the irritating effect of acetylsalicylic acid on the gastric mucosa. The most common use is 1 tablet of 150 mg per day during or after a meal. Tablets should be swallowed whole with a drink of water.

Indications

• zapobieganie zawałowi serca u osób dużego ryzyka,
• świeży zawał serca lub podejrzenie świeżego zawału serca,
• niestabilna choroba wieńcowa,
• prewencja wtórna u• prevention of myocardial infarction in high-risk individuals,
• fresh myocardial infarction or suspected fresh myocardial infarction,
• unstable coronary artery disease,
• secondary prevention in post-myocardial infarction patients,
• condition after coronary artery bypass grafting, coronary angioplasty,
• prevention of transient cerebral ischemia (TIA) attacks and ischemic stroke in patients with TIA,
• after ischemic stroke in patients with TIA,
• in patients with peripheral arteriosclerosis,
• prevention of coronary thrombosis in patients with multiple risk factors,
• prevention of venous thrombosis and pulmonary embolism in patients with prolonged immobilization, such as after major surgery, as an adjunct to other means of prophylaxis.
osób po przebytym zawale serca, • stan po wszczepieniu pomostów aortalno-wieńcowych, angioplastyce wieńcowej,
• zapobieganie napadom przejściowego niedokrwienia mózgu (TIA) i niedokrwiennego udaru mózgu u pacjentów z TIA,
• po przebytym udarze niedokrwiennym mózgu u pacjentów z TIA,
• u osób z zarostową miażdżycą tętnic obwodowych,
• zapobieganie zakrzepicy naczyń wieńcowych u pacjentów z mnogimi czynnikami ryzyka,
• zapobieganie zakrzepicy żylnej i zatorowi płuc u pacjentów długotrwale unieruchomionych, np. po dużych zabiegach chirurgicznych jako uzupełnienie innych sposobów profilaktyki.

Contraindications

Bonacard product should not be used:
• in case of hypersensitivity to the active substance acetylsalicylic acid, other salicylates or to any of the excipients listed in section 6.1,
• In patients with hemorrhagic diathesis,
• in patients with active gastric and/or duodenal ulcer disease,
• in patients with severe hepatic insufficiency,
• in patients with severe heart failure,
• in patients with a history of attacks of so-called aspirin asthma, induced by the administration of salicylates or substances with similar effects, especially non-steroidal anti-inflammatory drugs,
• concomitantly with methotrexate at doses of 15 mg per week or more (see section 4.5),
• in the last trimester of pregnancy,
• in children under 12 years of age in the course of viral infections due to the risk of Reye's syndrome, a rare but severe disease causing liver and brain damage.

Special precautions during storage

Store at temperatures below 25°C